Bone health in men with severe hemophilia a on two treatments
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at how two different hemophilia A treatments affect bone health over time. It tests if one medicine is better at keeping bones strong than the other.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 30 and 50 years old.
- You have severe hemophilia A (factor VIII level less than 1%).
- You have been taking either efanesoctocog alfa or emicizumab for at least 3 months and plan to stay on it for the next 5 years.
- Your weight is less than 300 pounds and your body mass index (BMI) is between 18.5 and 40.
- You are willing to have bone density tests (DEXA scans) and give blood samples.
- You do not have other bone-related diseases (like Paget's disease or osteogenesis imperfecta), active inhibitors, HIV, or advanced hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
This study looks at using long-term blood thinners (anticoagulants) in adults with severe hemophilia A, a bleeding disorder. It aims to understand if this treatment can be safe and effective for patients who may need it.
This trial compares two low-dose medicines to prevent bleeding episodes in people with severe hemophilia A: a newer medicine (emicizumab) versus the standard factor VIII treatment. It may help find a more convenient or effective way to reduce bleeding.
This study looks at how hemophilia A affects joint health, balance, and quality of life in adults. Researchers will assess your joints and balance to understand the relationship between joint damage and everyday function.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.